Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$13.05 +0.94%

+$0.15 today

Market cap
$331.67M
Beta
0.48
P/E (TTM)
9.3
EPS (TTM)
$1.22
52W Low $11.98High $20.56

Volume 0.04M

Average 0.03M

CPH.TO Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Cipher Pharmaceuticals Inc.TSX: CPH.TO

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow grows, but more slowly than its trailing trend

Q1 FY2026 free cash flow of $4.45M rose 5.4% year over year, behind the +40.8% change in trailing-twelve-month free cash flow. Sequentially, it fell 49.7% from the prior quarter. Over 3 fiscal years it compounded at +42.3% a year.

Context

  • Free cash flow amounted to 58.9% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Free cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +5.4% toward the trailing-twelve-month pace of +40.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.45M-49.7% QoQ
Last fiscal yearDec 2025
$30.22M+54.9% YoY
LTMMar 2026
$29.99M+40.8% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.4%——
1 year+54.9%——
3-year CAGR+42.3%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
30.22M USD
Year-over-year change
+54.9%
4-year CAGR
+21.6%

Free Cash Flow vs competitors

How CPH.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +40.8% is the 3rd highest of 8, against a peer median of -24.5%.
  • Free cash flow amounts to 58.9% of revenue for CPH.TO, versus a peer median of 14.9%.
CPH.TO Competitors
Free Cash Flow for CPH.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$77.34M CAD-56.3%-50.3%24.9%
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$76.19M CAD+602.1%+67.1%14.9%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$36.06M CAD+1163.3%-34.4%11.3%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$29.99M USD+40.8%+42.3%58.9%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$20.2M CAD-24.5%—7.4%
TSND.TOTerrAscend Corp.LTM Mar 2026$15.17M USD-31.1%—5.8%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$11.14M CAD+23.3%-0.7%403.5%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$7.86M USD-52.0%-6.7%15.4%
Peer median (excluding CPH.TO) —-24.5%-6.7%14.9%

Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.76M26.64M20.38M11.55M27.33M
Depreciation & Amortization701K989K1.23M4.02M7.23M
Deferred Income Tax(114K)(14.31M)(2.74M)(8.64M)(10.36M)
Stock-Based Compensation139K403K1.19M1.07M1.74M
Change in Working Capital4.68M(3.03M)(3.28M)8.95M5.32M
Accounts Receivables2.56M(144K)1.71M(8.77M)2.7M
Inventory(758K)(502K)(830K)3.6M(2.44M)
Accounts Payables(1.23M)(1.45M)532K1.28M527.07K
Other Working Capital4.11M(940K)(4.69M)12.85M4.53M
Other Non-Cash Items652K(109K)(788K)2.6M(1.01M)
Operating Cash Flow13.81M10.58M16M19.55M30.25M
Capital Expenditures0(81K)(144K)(44K)(28.49K)
Acquisitions (Net)0000132.28K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(123K)(80M)0
Investing Cash Flow0(81K)(144K)(80.04M)(72.24K)
Debt Repayment(828K)(56K)(111K)39.79M(35.61M)
Common Stock Issued0000218.76K
Common Stock Repurchased(1.72M)(1.99M)(5.56M)(176K)(5.48M)
Dividends Paid00000
Other Financing Activities75K132K426K(317K)(311.36K)
Financing Cash Flow(2.47M)(1.91M)(5.24M)39.3M(41.18M)
Effect of Forex Changes62K(292K)378K(786K)(194.92K)
Net Change in Cash11.41M8.29M10.99M(21.99M)(11.2M)
Free Cash Flow13.81M10.49M15.98M19.5M30.22M

Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Intrinsic Alpha fair value

Locked

Current Price

$13.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.